George Poste - 17 Jun 2025 Form 3 Insider Report for Caris Life Sciences, Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
3
Accepted by SEC
17 Jun 2025, 21:33:51 UTC
Prior SEC filing
30 May 2025
Next SEC filing
13 Aug 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ J. Russel Denton, Attorney-in-Fact

Key filing fact

George Poste filed Form 3 for Caris Life Sciences, Inc. on 17 Jun 2025.

Key facts

  • This page summarizes George Poste's Form 3 filing for Caris Life Sciences, Inc..
  • 0 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 17 Jun 2025, 21:33.

Change

  • Previous filing in this sequence was filed on 30 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001180770 Primary reporting owner

POSTE GEORGE

Relationship
Director
Address
C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
Signature
/s/ J. Russel Denton, Attorney-in-Fact
Signature date
17 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
234,754
Date
17 Jun 2025
Ownership
Direct
Footnotes
F1
CAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
307,594
Date
17 Jun 2025
Ownership
By Family Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CAI holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
125,000
Exercise price
$2.44
Footnotes
F2
CAI holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
50,000
Exercise price
$2.44
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Includes 234,754 shares of Common Stock underlying restricted stock units which vest in accordance with the applicable grant agreements.

Footnote F2

The stock option is fully vested and exercisable.

SEC remarks

Exhibit 24 - Power of Attorney.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .